Accelrys, Inc., the leading scientific informatics software and services company, is gaining momentum in the CPG market as key industry leaders adopt solutions utilizing predictive analytics to drive innovation productivity. The depth and value of Accelrys' scientific expertise is already proven across the life-sciences, biotech and chemical sectors, where researchers at the world's most innovative companies deploy solutions from Accelrys across their R&D enterprises.
Now, Accelrys is extending its success beyond these verticals into the CPG sector where R&D organizations are increasingly turning to high-throughput experimental techniques in order to hold down costs while increasing innovation productivity. Accelrys' Pipeline Pilot scientific informatics platform supports this research paradigm with tools to integrate data as diverse as analytical instrumentation results, chemical assays, consumer preference models, or market data -- all of which impact product performance.
R&D teams can become overwhelmed by the large amounts of data generated by high-throughput techniques that can mask key results. The predictive analytics available in Pipeline Pilot give R&D staff a handle on this problem, making it easy to see all of the results and identify the best leads for follow up. The recent introduction of the Materials Studio Collection for Pipeline Pilot extends this capability to predictive molecular modeling, generating additional data that can provide insight down to the molecular level.
"Finding, formatting and collating research data takes up precious development time," said Johan Aubert, Group Leader of Methods and Techniques for Development of L'Oreal S.A. "Streamlining these tasks is a critical component of success to support our High Throughput Experimentation (HTE) processes. By combining enterprise-level automation with real scientific know-how, Accelrys lets us unlock our high-value data and speed the innovation that drives revenue."
Pipeline Pilot also increases the productivity of R&D teams by automating complex, manual, and repetitive tasks, freeing up the researchers to spend more time innovating. Workflows can be encapsulated in web-based applications that can be made accessible across the enterprise to share information or to deploy best practices. This ensures that information is readily available for collaboration across the entire R&D enterprise and that scientists are able to focus their time on research rather than trying to find and access data.
Unlike traditional enterprise and data warehousing solutions that deal only with structured, alpha-numeric data, Accelrys' Pipeline Pilot and its scientific collections enable CPG organizations to easily access their research and formulation intellectual property -- including unstructured data that may be in the form of text, images, biological sequences or chemical models -- for collaboration and re-use. Accelrys offers a scientific informatics platform with a comprehensive line up of associated collections that can be used for data pipelining and predictive science.
"Consumer product companies face growing pressure to speed the product development cycle while improving product margins and driving top line growth," said Dr. Frank Brown, senior vice president and chief science officer of Accelrys. "At the same time, they are challenged in effectively utilizing the increasing volumes of highly complex and distributed scientific data -- a reality that, combined with regulatory mandates, can hamper efficiency. Accelrys helps organizations improve their research efficiency and get better, more innovative products to market ahead of the competition."
About Accelrys, Inc.
Headquartered in San Diego, California, Accelrys (accelrys.com, symyx.com) develops scientific informatics software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Its scientific informatics platform underlies the company's computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. In July 2010, Accelrys and Symyx Technologies, Inc. merged, combining the market-leading Symyx electronic laboratory notebook, decision support software, and chemical informatics and sourcing databases with the Accelrys portfolio of scientific informatics solutions.
Forward-Looking Statements This press release contains forward-looking statements. Such statements, including statements relating to the Company's products, their features, and their impact upon our customers' organizations, are subject to risks and uncertainties including, but not limited to, the risk that our products will not be successfully developed, achieve market acceptance, have the anticipated impact upon our customers' organizations, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.